Showing results (91-100 of 128) with videos related to
Sort By:
Pageof 13
Journal for Immunotherapy of Cancer|October 21, 2018
Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statementApostolia M Tsimberidou, Laura A Levit, Richard L Schilsky, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2018
Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer StatementApostolia M Tsimberidou, Laura A Levit, Richard L Schilsky, et al.Stem Cell Research|April 29, 2020
Generation of human induced pluripotent stem cells (NIHTVBi004-A, NIHTVBi005-A, NIHTVBi006-A, NIHTVBi007-A, NIHTVBi008-A) from 5 CADASIL patients with NOTCH3 mutationGuibin Chen, Zhongwen Li, Yangtengyu Liu, et al.Vascular Medicine (London, England)|June 4, 2025
Treated HIV infection is not associated with carotid vascular inflammation or plaque progression as assessed by dynamic contrast magnetic resonance imagingSaate Shakil, Daniel Chen, Daniel Isquith, et al.The Oncologist|February 14, 2018
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung CancerJoachim von Pawel, David R Spigel, Thomas Ervin, et al.Iscience|December 17, 2024
A combined AI and cell biology approach surfaces targets and mechanistically distinct Inflammasome inhibitorsDaniel Chen, Tempest Plott, Michael Wiest, et al.Human Molecular Genetics|September 10, 2002
Fine mapping of a multiple sclerosis locus to 2.5 Mb on chromosome 17q22-q24Janna Saarela, Marlena Schoenberg Fejzo, Daniel Chen, et al.Current Research in Translational Medicine|January 23, 2024
Cardiovascular risk in a contemporary cohort of patients with myeloproliferative neoplasms'Dipal Mehta, Samah Alimam, Donal P McLornan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2011
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanomaKevin B Kim, Jeffrey A Sosman, John P Fruehauf, et al.Research Square|October 27, 2023
An NKG2A biased immune response confers protection for infection, autoimmune disease, and cancerJames Heath, Daniel Chen, Jingyi Xie, et al.Pageof 13